Patients with schizophrenia, whose current medication is not fully effective, will participate in a clinical trial to see if CBD is safe and effective when used alongside an anti-psychotic drug, according to a newly registered clinical trial.
GW Pharmaceuticals’ research and development for the therapeutic use of cannabinoids dates back at least two decades.
First drug (Epidiolex) containing purified substance derived from marijuana was approved by U.S. FDA: We’ll continue to support rigorous scientific research on potential medical uses of marijuana-derived products,” said FDA Commissioner Scott .Gottlieb
Large clinical trial – King’s College London – seeks to affirm CBD as a treatment for psychosis..
“CBD has emerged as a promising candidate as it displays anti-anxiety and anti-psychotic like properties in animals and humans.”
Drug company earning multi-millions on MS med containing only 2 ingredients – THC and CBD ready to launch epilepsy drug this fall & now racing to develop CBD drugs for schizophrenia, #autism & other hard-to treat diseases.
CBD has beneficial effects in patients with schizophrenia and may represent a new class of treatment for the disorder.
With an FDA nod to GW Pharma, the CBD-based anti-seizure medication Epilodex will be on the market before the end of 2018. First-of-its kind medical trial seizures in children with a rare, life-threatening type of epilepsy.